drugset / Trial / NCT02598596
Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect
Non-randomizedSingle-groupOpen-labelOther
Summary
The purpose of this study is to evaluate the effect of a high zone tolerizing regimen of pegloticase on clinical outcome, as defined by an serum uric acid level \<6 mg/dL, in patients with chronic, refractory gout.
Timeline
- Start
- 2015-12
- Primary completion
- 2020-04-13
- Completion
- 2020-04-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegloticase | Protein / enzyme biologic | 8 mg | Intravenous |
| Background | Azathioprine | Small molecule | 2.5 mg/kg | Oral |